Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Immunome, Inc. (NASDAQ:IMNM) by 217.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 442,477 shares of the company’s stock after purchasing an additional 302,916 shares during the period. Charles Schwab Investment Management Inc. owned 0.74% of Immunome worth $6,469,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Arizona State Retirement System lifted its holdings in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after buying an additional 918 shares during the last quarter. Clear Creek Financial Management LLC boosted its holdings in Immunome by 18.2% in the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after purchasing an additional 4,035 shares during the period. AQR Capital Management LLC increased its stake in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Immunome during the second quarter worth $81,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Immunome in the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Activity at Immunome

In other news, CTO Philip Tsai purchased 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were bought at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Clay B. Siegall acquired 66,057 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 102,862 shares of company stock worth $978,045 in the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IMNM. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Stephens began coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Piper Sandler dropped their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has a consensus rating of “Buy” and an average price target of $28.83.

Immunome Price Performance

Shares of Immunome stock opened at $14.04 on Thursday. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96. The business’s fifty day moving average price is $12.24 and its two-hundred day moving average price is $13.47. The company has a market capitalization of $876.33 million, a P/E ratio of -1.73 and a beta of 1.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.